Back to results
US 2022/0064283 A1Published application
Antibodies and use thereof
AssigneeNovo Nordisk A/S
InventorsPeter Matthew Tessier, Samuel D. Stimple, Arne Staby
Life of this patent
Estimating the term…
Abstract
The present invention relates to specific antibodies and use thereof, such as for identifying and/or quantifying liraglutide fibrils and/or semaglutide fibrils.
Claims4
An antibody of SEQ ID NO:
- 109, or an antigen-binding fragment thereof, comprising:
- a heavy chain variable region comprising a CDR1, a CDR2, and a CDR3 sequence (H-CDR1, H-CDR2 and H-CDR3) and a light chain variable region of said antibody comprises a CDR1, a CDR2, and a CDR3 sequence (L-CDR1, L-CDR2 and L-CDR3) that is:
- SEQ ID NO:
- 120, 119, and 118 (H-CDR1, H-CDR2, and H-CDR3) and SEQ ID NO:
- 117, 116, and 115 (L-CDR1, L-CDR2, and L-CDR3);
- and
- wherein the antibody binds liraglutide fibrils.
4 more elements
Dependencies are inferred from the claim text.